In recent years, health insurers have argued that the high price
tags on drugs for rare diseases are unsustainable. For America’s
Health Insurance Plans (AHIP), an influential trade association,
reducing tax deductions and other incentives to develop rare
disease medicines under the 1983 Orphan Drug Act (ODA) is a
top agenda item. Deirdre Albertson and Judith Ng-Cashin of
Syneos Health identify the scenarios that worry health insurers
and the steps biopharmaceutical companies might take in